Evofem Biosciences Inc
Change company Symbol lookup
Select an option...
EVFM Evofem Biosciences Inc
FCO Aberdeen Global Income Fund Inc.
DTEC ALPS Disruptive Technologies ETF
$RUIRETAILT Russell 1000 RGS Retail Total Return
BAC Bank of America Corp
MA Mastercard Inc
AAPL Apple Inc
AA Alcoa Corp
AMD Advanced Micro Devices Inc
PFE Pfizer Inc
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Evofem Biosciences Inc, formerly Neothetics, Inc., is a clinical-stage specialty biopharmaceutical company. The Company develops products to address unmet needs in women's sexual and reproductive health. The Company’s product Amphora, is a Multipurpose Vaginal pH Regulator (MVP-R) designed to regulate vaginal pH to within the normal range of 3.5 to 4.5 even in the presence of semen. This maintains an acidic environment which is inhospitable to sperm as well as certain viral and bacterial pathogens associated with sexually transmitted infections. Amphora is used to prevent urogenital chlamydia and gonorrhea in women. The Company is in the second Phase III clinical trial of Amphora for prevention of pregnancy (AMP002). The Company is currently designing a Phase IIb trial for its second product candidate, a MVP-R to reduce the recurrence of bacterial vaginosis.

Closing Price
$2.71
Day's Change
0.02 (0.74%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.76
Day's Low
2.66
Volume
(Light)
Volume:
1,697,036

10-day average volume:
2,485,108
1,697,036

Display:

Providers:

UpdateCancel
6 providers

No press release found.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.